Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRIW) Cash & Current Investments (2020 - 2025)

Historic Cash & Current Investments for Biofrontera (BFRIW) over the last 6 years, with Q3 2025 value amounting to $3.4 million.

  • Biofrontera's Cash & Current Investments rose 1784.73% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 million, marking a year-over-year increase of 1784.73%. This contributed to the annual value of $5.9 million for FY2024, which is 31604.5% up from last year.
  • Biofrontera's Cash & Current Investments amounted to $3.4 million in Q3 2025, which was up 1784.73% from $7.2 million recorded in Q2 2025.
  • Biofrontera's 5-year Cash & Current Investments high stood at $31.9 million for Q2 2022, and its period low was $1.4 million during Q4 2023.
  • Its 5-year average for Cash & Current Investments is $11.4 million, with a median of $6.3 million in 2023.
  • In the last 5 years, Biofrontera's Cash & Current Investments soared by 150361.31% in 2022 and then tumbled by 9488.04% in 2023.
  • Quarter analysis of 5 years shows Biofrontera's Cash & Current Investments stood at $24.5 million in 2021, then increased by 13.08% to $27.8 million in 2022, then tumbled by 94.88% to $1.4 million in 2023, then soared by 316.05% to $5.9 million in 2024, then crashed by 42.03% to $3.4 million in 2025.
  • Its last three reported values are $3.4 million in Q3 2025, $7.2 million for Q2 2025, and $1.8 million during Q1 2025.